## AMENDMENTS TO THE CLAIMS

The claims in this listing will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims**

- 1. (Previously Presented) Use of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), the protected forms, salts and/or prodrugs thereof for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy, without an additional administration of cytostatics.
- 2. (Previously Presented) Use according to claim 1, characterized in that at least one cytostatic in conjunction with BVDU, the protected forms, salts and/or prodrugs thereof is used during chemotherapy.
- 3. (Previously Presented) Use according to claim 2, characterized in that, during chemotherapy, doses of the cytostatic increasing over a defined period in combination with a constant dose of BVDU, the protected forms, salts and/or prodrugs thereof are used and subsequent to the chemotherapy, i.e. in a recovery phase, the BVDU, the protected forms, salts and/or prodrugs thereof alone are used.
- 4. (Previously Presented) Use according to claim 3, characterized in that the duration of the recovery phase is from 3 to 10 days.

## P28506.A01

- 5. (Currently Amended) Use according to one of the claim 3 or 4 claim 3, characterized in that the duration of the chemotherapy cycle is from 8 to 30 days.
- 6. (Previously Presented) Use according to claim 1, characterized in that a compound of the general formula I

is used as prodrug.

7. (Currently Amended) Use according to at least one of claims 1 to 6 claim 1, characterized in that BVDU, the protected forms, salts and/or prodrugs thereof used in a dosage which makes possible a blood concentration between 0,02 and 50 µg/ml.